

CLAIMS

1. A bispecific antibody comprising:
a first antibody which comprises a heavy chain variable (VH) domain and a light
5 chain variable (VL) domain,
wherein the VH domain comprises:
the VH CDR1 sequence of SEQ ID NO: 1;
the VH CDR2 sequence of SEQ ID NO: 2 or SEQ ID NO: 43 and
the VH CDR3 sequence of SEQ ID NO: 3;
10 and wherein the VL domain comprises:
the VL CDR1 sequence of SEQ ID NO: 4;
the VL CDR2 sequence of SEQ ID NO: 5; and
the VL CDR3 sequence of SEQ ID NO: 6; and
a second antibody which binds to CD3 comprising a heavy chain having the
15 sequence of SEQ ID NO: 40.
2. The bispecific antibody according to claim 1, wherein the first antibody comprises
human variable domain framework regions.
- 20 3. The bispecific antibody according to any one of the preceding claims, wherein the
second antibody comprises a single chain variable fragment (scFv).
4. The bispecific antibody according to any one of the preceding claims, wherein the
first antibody is IgG1 or IgG2.
- 25 5. Use of the bispecific antibody according to any one of the preceding claims in the
manufacture of a medicament for treating a CD43 positive tumor or cancer in a subject,
wherein the CD43 positive tumor or cancer expresses the UMG1 epitope.

6. The use according to claim 5, wherein the CD43 positive tumor or cancer expressing the UMG1 epitope is selected from the group consisting of: diffuse large B cell lymphoma, MALT lymphoma, Burkitt's lymphoma, anaplastic large cell lymphoma, follicular lymphoma, mantle cell lymphoma, multiple myeloma, melanoma, testicular cancer, nephroblastoma, neuroblastoma, endodermal sinus carcinoma, retinoblastoma, hepatoblastoma, medulloblastoma, choroid plexus papilloma, glioblastoma, ependymoma, primitive neuroectodermal tumor, alveolus rhabdomyosarcoma, immaturity teratoma, and leiomyosarcoma.
7. The use according to claim 6, wherein the testicular cancer is selected from the group consisting of seminoma, embryonal carcinoma, yolk sac tumor, and teratoma.